Option Care Health Announces Financial Results for the Third Quarter Ended September 30, 2022
BANNOCKBURN, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH),...
Day: October 27, 2022
Aurora Spine Corporation Announces Positive Interim Results from Clinical Study using ZIP™ MIS Interspinous Fusion System
Initial results show ZIP device to be effective and safeCARLSBAD, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Aurora Spine Corporation...
Indigo Diabetes Incorporates Fully Owned Subsidiary in the US and Appoints Peter J. Devlin as President, Indigo Medical US Inc.
PRESS RELEASE Indigo Diabetes Incorporates Fully Owned Subsidiary in the US and Appoints Peter J. Devlin as President, Indigo Medical...
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update
-- U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway -- -- Commenced Launch of...
BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022
NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence...
TELA Bio to Announce Third Quarter 2022 Financial Results
MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing...
Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award
Katherine Donovan, Ph.D. of the Dana-Farber Cancer Institute has been awarded a $25,000 monetary prize recognizing her innovation in the field...
Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Disease
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic...
Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a...